Technical Analysis for GDTC - CytoMed Therapeutics Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.77 | -1.07% | -0.03 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -1.07% | |
| NR7 | Range Contraction | -1.07% | |
| Narrow Range Bar | Range Contraction | -1.07% | |
| Inside Day | Range Contraction | -1.07% | |
| Up 3 Days in a Row | Strength | -1.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 12 hours ago |
| Rose Above 20 DMA | about 12 hours ago |
| 10 DMA Support | about 12 hours ago |
| Rose Above Previous Day's High | about 12 hours ago |
| Outside Day | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapies Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.8 |
| 52 Week Low | 2.36 |
| Average Volume | 146,612 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 2.84 |
| 10-Day Moving Average | 2.75 |
| Average True Range | 0.27 |
| RSI (14) | 38.65 |
| ADX | 8.84 |
| +DI | 13.49 |
| -DI | 16.96 |
| Chandelier Exit (Long, 3 ATRs) | 3.99 |
| Chandelier Exit (Short, 3 ATRs) | 3.17 |
| Upper Bollinger Bands | 3.06 |
| Lower Bollinger Band | 2.61 |
| Percent B (%b) | 0.35 |
| BandWidth | 15.89 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.20 |
| MACD Histogram | 0.0239 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.92 | ||||
| Resistance 3 (R3) | 2.93 | 2.89 | 2.90 | ||
| Resistance 2 (R2) | 2.89 | 2.85 | 2.89 | 2.89 | |
| Resistance 1 (R1) | 2.83 | 2.83 | 2.86 | 2.82 | 2.88 |
| Pivot Point | 2.79 | 2.79 | 2.81 | 2.79 | 2.79 |
| Support 1 (S1) | 2.73 | 2.75 | 2.76 | 2.72 | 2.66 |
| Support 2 (S2) | 2.69 | 2.73 | 2.69 | 2.65 | |
| Support 3 (S3) | 2.63 | 2.69 | 2.65 | ||
| Support 4 (S4) | 2.62 |
